S100A9 as a novel diagnostic and prognostic biomarker in human gastric cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Grunnet M, Mau-Sørensen M, Brünner N. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol. 2013;48(8):899–905.
   PubMed Web of Science ®Google Scholar
• Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol. 2007;42(1):2–10.
   PubMed Web of Science ®Google Scholar
• Nunez-Naveira L, Marinas-Pardo LA, Montero-Martinez C. Mass spectrometry analysis of the exhaled breath condensate and proposal of dermcidin and S100A9 as possible markers for lung cancer prognosis. Lung 2019;197(4):523–531.
   PubMed Web of Science ®Google Scholar
• Zhou M, Li M, Liang X, et al. The significance of serum S100A9 and TNC levels as biomarkers in colorectal cancer. J Cancer 2019;10(22):5315–5323.
   PubMed Web of Science ®Google Scholar
• Choi JH, Shin NR, Moon HJ, et al. Identification of S100A8 and S100A9 as negative regulators for lymph node metastasis of gastric adenocarcinoma. Histol Histopathol. 2012;27(11):1439–1448.
   PubMed Web of Science ®Google Scholar
• Kwon CH, Moon HJ, Park HJ, et al. S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-kappaB activation in gastric cancer cells. Mol Cells 2013;35(3):226–234.
   PubMed Web of Science ®Google Scholar
• Yong HY, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res. 2007;30(1):75–81.
   PubMed Web of Science ®Google Scholar
• Wang Q, Du J, Yu P, et al. Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis. Sci Rep. 2015;5(1):17833.
   PubMed Web of Science ®Google Scholar
• Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–552.
   PubMed Web of Science ®Google Scholar
• Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the Cancer Genome Atlas. Cell 2018;173(2):321–337.
   PubMed Web of Science ®Google Scholar
• Kim J, Kwiatkowski D, McConkey DJ, et al. The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur Urol. 2019;75(6):961–964.
   PubMed Web of Science ®Google Scholar
• Huo D, Hu H, Rhie SK, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017;3(12):1654–1662.
   PubMed Web of Science ®Google Scholar
• Liu L, Hu X, Sun D, et al. ZIC5 facilitates the growth of hepatocellular carcinoma through activating Wnt/beta-catenin pathway. Biochem Biophys Res Commun. 2018;503(3):2173–2179.
   PubMed Web of Science ®Google Scholar
• Fan B, Zhang LH, Jia YN, et al. Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC Cancer 2012;12(1):316.
   PubMed Web of Science ®Google Scholar
• Sheikh AA, Vimalachandran D, Thompson CC, et al. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics 2007;7(11):1929–1940.
   PubMed Web of Science ®Google Scholar
• Ang CW, Nedjadi T, Sheikh AA, et al. Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis 2010;31(9):1541–1551.
   PubMed Web of Science ®Google Scholar
• Hermani A, Hess J, De SB, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11(14):5146–5152.
   PubMed Web of Science ®Google Scholar
• Kawai H, Minamiya Y, Takahashi N. Prognostic impact of S100A9 overexpression in non-small cell lung cancer. Tumor Biol. 2011;32(4):641–646.
   PubMedGoogle Scholar
• Arai K, Teratani T, Kuruto-Niwa R, et al. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 2004;40(8):1179–1187.
   PubMed Web of Science ®Google Scholar
• Swann JB, Vesely MD, Silva A, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA. 2008;105(2):652–656.
   PubMed Web of Science ®Google Scholar
• Wagner NB, Weide B, Gries M, et al. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. J Immunother Cancer 2019;7(1):343.
   PubMed Web of Science ®Google Scholar
• Ghavami S, Chitayat S, Hashemi M, et al. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 2009;625(1–3):73–83.
   PubMed Web of Science ®Google Scholar
• Moon A, Yong HY, Song JI, et al. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res. 2008;6(10):1544–1553.
   PubMed Web of Science ®Google Scholar
• Ghavami S, Rashedi I, Dattilo BM, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol. 2008;83(6):1484–1492.
   PubMed Web of Science ®Google Scholar